XM does not provide services to residents of the United States of America.
G
G

GSK

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Iteos And GSK Initiate Phase 3 Study Assessing Belrestotug And Dostarlimab In Non-Small Cell Lung Cancer

BRIEF-Iteos And GSK Initiate Phase 3 Study Assessing Belrestotug And Dostarlimab In Non-Small Cell Lung Cancer June 17 (Reuters) - GSK plc GSK.L : ITEOS AND GSK INITIATE GALAXIES LUNG-301 PHASE 3 STUDY, ASSESSING BELRESTOTUG AND DOSTARLIMAB IN PREVIOUSLY UNTREATED, UNRESECTABLE LOCALLY ADVANCED / METASTATIC PD-L1 SELECTED NON-SMALL CELL LUNG CANCER
G

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation

BRIEF-GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation June 11 (Reuters) - GSK plc GSK.L : STATEMENT: ZANTAC (RANITIDINE) LITIGATION DELAWARE SUPERIOR COURT'S RULING INCONSISTENT WITH HOW DAUBERT STANDARD* HAS PREVIOUSLY BEEN APPLIED IN DELAWARE AND FEDERAL COURTS APPLICATION HAS BEEN FILED SEEKING RIGHT
G

British Business - June 11

PRESS DIGEST-British Business - June 11 June 11 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
B
B
B
G
P

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

UPDATE 1-GSK asks to appeal Delaware ruling allowing Zantac cases to go forward Recasts headline, paragraphs 1-4 with appeal petition By Brendan Pierson June 10 (Reuters) - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
G
P
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.